Featured Research

from universities, journals, and other organizations

Hot flashes/night sweats solutions: Estrogen therapy vs. Venlafaxine

Date:
May 26, 2014
Source:
Brigham and Women's Hospital
Summary:
A new study that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women. The objective of the study was to determine the therapeutic benefit and tolerability of low-dose estradiol and low-dose venlafaxine in alleviating hot flashes and night sweats.

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women. The study is the first clinical trial to simultaneously evaluate estrogen therapy (ET), known as the "gold standard" treatment for hot flashes and night sweats, and a non-hormonal treatment, venlafaxine, a first-line treatment in women who are unwilling or unable to use ET.

The study titled, "Randomized Controlled Trial of Low-Dose Estradiol and the Serotonin-Norepinephrine" is published in the May 27 issue of JAMA Internal Medicine.

"Since the publication of the Women's Health Initiative findings, which demonstrated risks associated with ET and led to our current recommendations -- that ET be used only at the lowest possible dosage for the shortest possible duration -- there has been increased interest in non-hormonal treatments. Our new findings provide critical data for physicians and women making treatment decisions for hot flashes/night sweats. Our data show that first-line hormonal and non-hormonal pharmacological treatments are well-tolerated and effective options for alleviating symptoms," said Hadine Joffe, MD, MSc, director of the Women's Hormone and Aging Research Program at BWH, and lead author of the paper. "Hot flashes and night sweats known as vasomotor symptoms (VMS) affect up to 80 percent of women in midlife and are the primary menopause-related symptoms leading menopausal women to seek medical attention."

In total, 339 perimenopausal and postmenopausal women with bothersome VMS were recruited from the community to Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH), National Institutes of Health (NIH)-sponsored clinical trial network sites between December 5, 2011 and October 15, 2012.

The objective of the study was to determine the therapeutic benefit and tolerability of low-dose estradiol and low-dose venlafaxine in alleviating hot flashes and night sweats. Participants were randomized to double-blind treatment with low-dose treatments for eight weeks. The primary outcome was the daily number of hot flashes and night sweats after treatment. After eight weeks, the frequency of hot flashes/night sweats decreased by 52.9 percent with estradiol, 47.6 percent with venlafaxine, and by 28.6 percent with placebo. On average, estradiol reduced the frequency of symptoms by 2.3 more per day than placebo, and venlafaxine reduced the frequency of symptoms by 1.8 more per day than placebo. The ameliorative effect on hot flashes/night sweats was statistically significant for each of the medications compared to placebo. Low-dose estradiol reduced the frequency of symptoms by 0.6 more per day compared to venlafaxine on average, although this difference was not statistically significant. While the benefit of low-dose estradiol was found to be slightly superior to venlafaxine in this study, the difference was found to be small and likely of limited clinical relevance.

Secondary outcomes were hot flash/night sweat severity and the interference of symptoms with daily life. The results for these outcomes were consistent with those for hot flash and night sweat frequency. Treatment satisfaction was highest for estradiol, intermediate for venlafaxine, and lowest for placebo. Both interventions were well-tolerated.


Story Source:

The above story is based on materials provided by Brigham and Women's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hadine Joffe, Katherine A. Guthrie, Andrea Z. LaCroix, Susan D. Reed, Kristine E. Ensrud, JoAnn E. Manson, Katherine M. Newton, Ellen W. Freeman, Garnet L. Anderson, Joseph C. Larson, Julie Hunt, Jan Shifren, Kathryn M. Rexrode, Bette Caan, Barbara Sternfeld, Janet S. Carpenter, Lee Cohen. Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. JAMA Internal Medicine, 2014; DOI: 10.1001/jamainternmed.2014.1891

Cite This Page:

Brigham and Women's Hospital. "Hot flashes/night sweats solutions: Estrogen therapy vs. Venlafaxine." ScienceDaily. ScienceDaily, 26 May 2014. <www.sciencedaily.com/releases/2014/05/140526182751.htm>.
Brigham and Women's Hospital. (2014, May 26). Hot flashes/night sweats solutions: Estrogen therapy vs. Venlafaxine. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/05/140526182751.htm
Brigham and Women's Hospital. "Hot flashes/night sweats solutions: Estrogen therapy vs. Venlafaxine." ScienceDaily. www.sciencedaily.com/releases/2014/05/140526182751.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins